Pulmonary Drug Delivery of Budesonide in the Form of Inhalable Microspheres

ABSTRACT

Objectives: Chronic Obstructive Pulmonary Disease (COPD) is a major healthcare issue that is rising and expected to increase in day-to-day life. Our research work focused on developing Dry Powder Inhaler (DPI) microspheres that deliver medication in the form of dry powder into the lungs. Budesonide was used as a drug along with Polycaprolactone which is a biodegradable and biocompatible polymer used in the formulation of microspheres. Due to its non-toxicity with many drugs, it is suitable for controlled release. Materials and Methods: The microspheres were formulated using solvent evaporation technique and evaluation parameters such as size, shape, drug loading, and entrapment efficiency for better patient compliance and treatment were performed. Results: The microsphere had particle size ranging from 1 μm-5 μm, within the inhalable range. The morphological study showed a smooth surface area with spherical-shaped particles. The particles were monodispersed with PDI less than 0.5. The % drug release was found to be 95.3% after 48 hr showing sustained drug release from Polycaprolactone microspheres. The in vivo study suggested that the given formulation effectively inhibited the LPS-induced toxicity in a dose-dependent fashion and proved to be anti-inflammatory. Conclusion: Budesonide inhalable microsphere of Polycaprolactone was proven to be beneficial without any toxicity for the treatment of coronary obstructive pulmonary technique.

KEYWORDS

• Microspheres
• Biodegradable
• Inhalation
• Polycaprolactone
• COPD
• Kinetics

Showing references and in-text citations exactly as published.

• DOI10.5530/ijper.20261573Copy

RELATED ARTICLES

Matched on section and article type within this issue of IJPER.

• Article · VOLUME 60, ISSUE 1SThe Role of EPAC in the Pathogenesis of Cardiovascular Complications: A ReviewNandini Dubey, Vishal Kumar Vishwakarma, Aanchal Verma, Ahsas Goyal, Harlokesh Narayan Yadav · pp. s1–s10Research ArticleSame type: Article
• Article · VOLUME 60, ISSUE 1SGlobal Comparison of Gene and Cell Therapy Regulations: A Cross-Regional Analysis of FDA, EMA, TGA, CSFDA, DCGI, PMDA, IFDA and MFDSSeyed Heidar Mohammadi, Gholamhossein Sadeghian, Hoseein Shomali, Mohamadreza Abedi, Behrooz Jannat, Faham Khamesipour · pp. s18–s32Research ArticleSame type: Article
• Article · VOLUME 60, ISSUE 1SReview on Exploring the Combination Effect of Aldosterone along with Plasma Renin with Melatonin and Hydro-Cortisol in Diurnal RhythmMainak Pal, Masud Sk, Saheli Mandal, Dipanjan Mandal · pp. s33–s41Research ArticleSame type: Article
• Article · VOLUME 60, ISSUE 1SRegulatory Pathway for Genotoxic Impurities in Europe, US, Canada, India, Australia and UKKavyashree Kadehalli Ramegowda, Sangita Mishra, Venkatesh Madhugiri Prakash · pp. s42–s51Research ArticleSame type: Article